X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EdiGene’s high-throughput genome-editing screening platform uses high-throughput screening and bioinformatics analysis to develop new biomarkers and potential targeted therapies.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Peking University Cancer Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 13, 2022
Details:
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell).
Lead Product(s): iPSC-CAR-NK Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Neukio Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 09, 2022
Details:
Partnering with leading engineered cell therapy developers is a key component of Arbor’s strategy to broaden the potential of CRISPR discovery engine beyond the wholly-owned in vivo genetic medicine approaches for the benefit of even more patients.
Lead Product(s): Ex-vivo Engineered Cell Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: Arbor Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 08, 2022
Details:
Under the agreement, both parties will develop hematopoietic stem cell regenerative therapies, ET-01, including the development of genetically-modified hematopoietic stem cell therapies and exploration of novel biomarkers to optimize quality control for stem cell production.
Lead Product(s): ET-01
Therapeutic Area: Genetic Disease Product Name: ET-01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Haihe Laboratory
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 24, 2022
Details:
Under the partnership, EdiGene will work with the David Gamm Laboratory to evaluate the pharmacological property of LEAPER™ RNA employs short engineered ADAR-recruiting RNAs (arRNAs) base editing candidates targeting specific genetic diseases.
Lead Product(s): Short Engineered ADAR-recruiting RNAs
Therapeutic Area: Genetic Disease Product Name: arRNAs
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Wisconsin–Madison
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 09, 2021
Details:
ET-01 is an autologous, in vitro gene editing therapy product in the research and development stage. The clinical trial approved this time is a multi-center, open, single-arm clinical study.
Lead Product(s): ET-01
Therapeutic Area: Genetic Disease Product Name: ET-01
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2021
Details:
EdiGene has established four gene editing based platforms and is advancing its early stage programs into clinical development for patients with genetic diseases and cancer. Proceeds from the financing will be used to advance the company’s pipeline into clinics.
Lead Product(s): ET-01
Therapeutic Area: Genetic Disease Product Name: ET-01
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: 3H Health Investment
Deal Size: $67.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
